Allergic rhinitis (AR) is a prevalent disorder that causes a significant and often underestimated health burden for individuals and society. The current drug treatment cannot essentially deal with the regulation of the allergic reaction, while the allergic symptoms could be alleviated. Mesenchymal stem cells (MSCs) bear a variety of properties, such as the ability to differentiate into various cell lineages, to secrete soluble factors crucial for cell survival and proliferation, to migrate to the exact site of injury, and to modulate the immune response. Clinical studies have been extensively conducted in MSCs as the models for varieties of diseases such as neurological diseases. Due to their immunomodulatory properties, the MSCs have gradually been believed to become one of the promising strategies for AR treatments although so far the MSCs-mediated treatment for AR is still at animal experiments stage. Fully understanding the roles and mechanisms of MSCs immunomodulatory effects serves as the prerequisite that will be beneficial to the application of MSCs-based AR clinical treatment methods. In this review article, we highlighted the recent research advances and give a brief perspective in the future study of the MSCs-mediated therapeutic application in AR treatments.

中文翻译：

---

基于间充质干细胞的过敏性鼻炎治疗。

变应性鼻炎（AR）是一种普遍的疾病，对个人和社会造成重大且常常被低估的健康负担。当前的药物治疗基本上不能处理过敏反应的调节，同时可以减轻过敏症状。间充质干细胞（MSC）具有多种特性，例如分化为各种细胞谱系的能力，分泌对细胞存活和增殖至关重要的可溶性因子，迁移到损伤的确切位置以及调节免疫反应的能力。在MSC中已经广泛进行了临床研究，作为多种疾病例如神经系统疾病的模型。由于它们的免疫调节特性，尽管迄今为止，MSCs介导的AR治疗仍处于动物实验阶段，但MSC已逐渐被认为是AR治疗的有希望的策略之一。充分了解MSCs免疫调节作用的作用和机制是前提，这将有利于基于MSCs的AR临床治疗方法的应用。在这篇综述文章中，我们重点介绍了最近的研究进展，并在将来对MSCs介导的AR治疗中的治疗应用的研究中给出了简要的展望。